Liposomal Irinotecan Shows a Larger Therapeutic Index than Non-liposomal Irinotecan in Patient-Derived Xenograft Models of Pancreatic Cancer

INTRODUCTION: Liposomal irinotecan promotes controlled sustained release of irinotecan (CPT-11), therefore, we hypothesize that the therapeutic index (quantitative measurement of the relative efficacy/safety ratio of a drug) will be higher for liposomal than non-liposomal irinotecan. METHODS: We com...

Descripción completa

Detalles Bibliográficos
Autores principales: Barbier, Sandrine, Beaufils, Benjamin, de Miguel, Ricardo, Reyre, Melissa, Le Meitour, Yannick, Lortie, Andreanne, de Boisferon, Marc Hillairet, Chaumeron, Sophie, Espirito, Anne, Fossati, Lina, Lagarde, Pauline, Klinz, Stephan, Thiagalingam, Arunthathi, Lezmi, Stéphane, Meyer-Losic, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935793/
https://www.ncbi.nlm.nih.gov/pubmed/36645622
http://dx.doi.org/10.1007/s40487-022-00215-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935793/
https://www.ncbi.nlm.nih.gov/pubmed/36645622
http://dx.doi.org/10.1007/s40487-022-00215-2

Ejemplares similares